FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)
FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)
232 FOLLOWERS
FDA Drug Information Soundcast in Clinical Oncology (DISCO) is an FDA podcast series that provides information about new product approvals, emerging safety information for cancer treatments, and other current topics in cancer drug development.
FDA D.I.S.C.O. Burst Edition: FDA approval of OGSIVEO (nirogacestat) for adult patients with progressing desmoid tumors who require systemic treatment
FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)
by U.S. Food and Drug Administration, Center for Drug Evaluation and Research
3M ago
Listen to a soundcast of the November 27, 2023 FDA approval of OGSIVEO (nirogacestat) for adult patients with progressing desmoid tumors who require systemic treatment ..read more
Visit website
FDA D.I.S.C.O. Burst Edition: FDA approval of Augtyro (repotrectinib) for locally advanced or metastatic ROS1-positive non-small cell lung cancer
FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)
by U.S. Food and Drug Administration, Center for Drug Evaluation and Research
3M ago
FDA D.I.S.C.O. Burst Edition: FDA approval of Augtyro (repotrectinib) for locally advanced or metastatic ROS1-positive non-small cell lung cancer ..read more
Visit website
FDA D.I.S.C.O. Burst Edition: FDA approval of Fruzaqla (fruquintinib) for adult patients with metastatic colorectal cancer
FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)
by U.S. Food and Drug Administration, Center for Drug Evaluation and Research
3M ago
FDA D.I.S.C.O. Burst Edition: FDA approval of Fruzaqla (fruquintinib) for adult patients with metastatic colorectal cancer ..read more
Visit website
FDA D.I.S.C.O. Burst Edition: FDA approval of Tibsovo (ivosidenib) for patients with relapsed or refractory myelodysplastic syndromes with a susceptible isocitrate dehydrogenase-1 mutation
FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)
by U.S. Food and Drug Administration, Center for Drug Evaluation and Research
5M ago
FDA D.I.S.C.O. Burst Edition: FDA approval of Tibsovo (ivosidenib) for patients with relapsed or refractory myelodysplastic syndromes with a susceptible isocitrate dehydrogenase-1 mutation ..read more
Visit website
FDA D.I.S.C.O. Burst Edition: FDA approvals of Talvey (talquetamab-tgvs) for relapsed or refractory multiple myeloma, and Elrexfio (elranatamab-bcmm) for relapsed or refractory multiple myeloma
FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)
by U.S. Food and Drug Administration, Center for Drug Evaluation and Research
7M ago
FDA D.I.S.C.O. Burst Edition: FDA approvals of Talvey (talquetamab-tgvs) for relapsed or refractory multiple myeloma, and Elrexfio (elranatamab-bcmm) for relapsed or refractory multiple myeloma ..read more
Visit website
FDA D.I.S.C.O. Burst Edition: FDA approval of Lynparza (olaparib), with abiraterone and prednisone, for BRCA-mutated metastatic castration-resistant prostate cancer
FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)
by U.S. Food and Drug Administration, Center for Drug Evaluation and Research
10M ago
Listen to a soundcast of the May 31, 2023, FDA approval of Lynparza (olaparib), with abiraterone and prednisone, for BRCA-mutated metastatic castration-resistant prostate cancer ..read more
Visit website
FDA D.I.S.C.O. Burst Edition: FDA approval of Epkinly (epcoritamab-bysp) for relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma
FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)
by U.S. Food and Drug Administration, Center for Drug Evaluation and Research
11M ago
Listen to a soundcast of the May 19, 2023, FDA approval of Epkinly (epcoritamab-bysp) for relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma ..read more
Visit website
FDA D.I.S.C.O. Burst Edition: FDA approval of Polivy (polatuzumab vedotin-piiq) for previously untreated diffuse large B-cell lymphoma, not otherwise specified, and high-grade B-cell lymphoma
FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)
by U.S. Food and Drug Administration, Center for Drug Evaluation and Research
11M ago
Listen to a soundcast of the April 19, 2023, FDA approval of Polivy (polatuzumab vedotin-piiq) for previously untreated diffuse large B-cell lymphoma, not otherwise specified, and high-grade B-cell lymphoma ..read more
Visit website
FDA D.I.S.C.O. Burst Edition: FDA approval of Zynyz (retifanlimab-dlwr) for metastatic or recurrent locally advanced Merkel cell carcinoma
FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)
by U.S. Food and Drug Administration, Center for Drug Evaluation and Research
1y ago
Lsten to a soundcast of the March 22, 2023 FDA approval of Zynyz (retifanlimab-dlwr) for metastatic or recurrent locally advanced Merkel cell carcinoma ..read more
Visit website
FDA D.I.S.C.O. Burst Edition: FDA approval of Tafinlar (dabrafenib) with Mekinist (trametinib) for pediatric patients with low-grade glioma with a BRAF V600E mutation
FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)
by U.S. Food and Drug Administration, Center for Drug Evaluation and Research
1y ago
Listen to a soundcast of the March 16, 2023, FDA approval of Tafinlar (dabrafenib) for pediatric patients with low-grade glioma with a BRAF V600E mutation ..read more
Visit website

Follow FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.) on FeedSpot

Continue with Google
Continue with Apple
OR